ABSTRACT

High Throughput Screening (HTS) is widely becoming recognised as an important tool for the discovery of novel leads which can be further developed into pharmaceutical agents. The requirement for new chemical leads has arisen as a consequence of our greater understanding of the mechanisms responsible for disease processes, resulting in the identification of new biological targets. In many cases these targets have no pharmacological precedence and a conventional discovery program cannot be initiated.